Video Experimental Relacionado
Updated: Jan 18, 2026
13:07
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
Published on: January 15, 2022
4.4K
Angiología: Novedades en 2025
Abdelwahab Boulekbache1, Marc Righini1
1Service d'angiologie et hémostase, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue medicale suisse
|January 16, 2026
Resumen
Tres estudios de 2025 avanzaron en el tratamiento del tromboembolismo venoso (TEV). Se investigaron pruebas de dímero D ajustadas por edad para la trombosis venosa profunda, la eficacia de apixaban vs. rivaroxaban y la anticoagulación extendida para el TEV por cáncer.
Área de la Ciencia:
- Medicina Vascular
- Hematología
- Trombosis Clínica
Sus antecedentes:
- El tromboembolismo venoso (TEV) sigue siendo un desafío clínico importante.
- Las estrategias diagnósticas y los protocolos de tratamiento para el TEV requieren un refinamiento continuo.
- La optimización de la anticoagulación en poblaciones de pacientes específicas, como aquellas con cáncer, es crucial.
Objetivo del estudio:
- Presentar los hallazgos clave de tres estudios prospectivos importantes que impactan el manejo del TEV en 2025.
- Destacar los avances en la precisión diagnóstica, la eficacia comparativa del tratamiento y las estrategias de anticoagulación extendida para el TEV.
Principales métodos:
- El estudio ADJUST-DVT validó los umbrales de dímero D ajustados por edad para el diagnóstico de trombosis venosa profunda (TVP).
- El ensayo COBRRA comparó prospectivamente apixaban y rivaroxaban para el tratamiento de TEV agudo.
- El estudio API-CAT evaluó la apixaban extendida a dosis reducida para TEV asociado a cáncer.
Principales resultados:
- Los umbrales de dímero D ajustados por edad demostraron utilidad en el diagnóstico de TVP.
- Apixaban y rivaroxaban mostraron seguridad y eficacia comparables en el tratamiento de TEV agudo.
- La apixaban a dosis reducida proporcionó una alternativa potencial para la anticoagulación extendida en TEV asociado a cáncer, equilibrando la eficacia y el riesgo de sangrado.
Conclusiones:
- Estos estudios ofrecen enfoques refinados para el diagnóstico y manejo del TEV.
- Los datos comparativos sobre anticoagulantes orales directos (AOD) informan las opciones de tratamiento.
- Las estrategias de anticoagulación personalizadas, particularmente en grupos de alto riesgo, están avanzando en la atención del TEV.
Videos de Conceptos Relacionados
01:29Angina III: Clinical Manifestations and Assessment
203
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
203
01:26Angina IV: Management
238
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
238
01:20Angina V: Nursing Management
296
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
296
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
471
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
471
01:27Angina II: Classification
332
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
332